MX2024002146A - Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. - Google Patents
Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.Info
- Publication number
- MX2024002146A MX2024002146A MX2024002146A MX2024002146A MX2024002146A MX 2024002146 A MX2024002146 A MX 2024002146A MX 2024002146 A MX2024002146 A MX 2024002146A MX 2024002146 A MX2024002146 A MX 2024002146A MX 2024002146 A MX2024002146 A MX 2024002146A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- formula
- conditions related
- pcsk9 activity
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234973P | 2021-08-19 | 2021-08-19 | |
| US202163251972P | 2021-10-04 | 2021-10-04 | |
| US202163263095P | 2021-10-27 | 2021-10-27 | |
| US202263311622P | 2022-02-18 | 2022-02-18 | |
| US202263371685P | 2022-08-17 | 2022-08-17 | |
| PCT/US2022/040747 WO2023023245A1 (en) | 2021-08-19 | 2022-08-18 | Compounds for treating conditions related to pcsk9 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002146A true MX2024002146A (es) | 2024-03-08 |
Family
ID=83319263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002146A MX2024002146A (es) | 2021-08-19 | 2022-08-18 | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240238367A1 (https=) |
| EP (1) | EP4387645A1 (https=) |
| JP (1) | JP2024532129A (https=) |
| KR (1) | KR20240050369A (https=) |
| AU (1) | AU2022330007A1 (https=) |
| CA (1) | CA3228604A1 (https=) |
| IL (1) | IL310851A (https=) |
| MX (1) | MX2024002146A (https=) |
| WO (1) | WO2023023245A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025042927A2 (en) * | 2023-08-24 | 2025-02-27 | Merck Sharp & Dohme Llc | Sustained-release formulations for poorly permeable cyclic peptides |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| KR100818845B1 (ko) | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제 |
| AU7705601A (en) | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CN100457730C (zh) | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| EP1546142A4 (en) | 2002-08-29 | 2007-10-17 | Merck & Co Inc | INDOLES HAVING ANTIDIABETIC EFFECT |
| AU2004207444B2 (en) | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| IL279363B2 (en) | 2018-06-21 | 2025-12-01 | Merck Sharp & Dohme | Pcsk9 antagonist compounds |
| EP4021919A1 (en) * | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
-
2022
- 2022-08-18 IL IL310851A patent/IL310851A/en unknown
- 2022-08-18 JP JP2024509031A patent/JP2024532129A/ja active Pending
- 2022-08-18 CA CA3228604A patent/CA3228604A1/en active Pending
- 2022-08-18 KR KR1020247008443A patent/KR20240050369A/ko active Pending
- 2022-08-18 WO PCT/US2022/040747 patent/WO2023023245A1/en not_active Ceased
- 2022-08-18 AU AU2022330007A patent/AU2022330007A1/en active Pending
- 2022-08-18 US US18/684,095 patent/US20240238367A1/en active Pending
- 2022-08-18 EP EP22769816.4A patent/EP4387645A1/en active Pending
- 2022-08-18 MX MX2024002146A patent/MX2024002146A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024532129A (ja) | 2024-09-05 |
| AU2022330007A1 (en) | 2024-02-15 |
| CA3228604A1 (en) | 2023-02-23 |
| IL310851A (en) | 2024-04-01 |
| KR20240050369A (ko) | 2024-04-18 |
| EP4387645A1 (en) | 2024-06-26 |
| US20240238367A1 (en) | 2024-07-18 |
| WO2023023245A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5765739B2 (ja) | ロスバスタチンラクトールの薬物としての使用 | |
| EP4660303A3 (en) | Pcsk9 antagonist compounds | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| TNSN05037A1 (fr) | Derives heterobiaryliques servant d'inhibiteurs de metalloproteinases de matrice | |
| JPH05255084A (ja) | 経皮的冠動脈形成術後の再狭窄抑制剤 | |
| FR2608045A1 (fr) | Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome | |
| MA63589B1 (fr) | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle | |
| TNSN04212A1 (fr) | Sels de tolterodine | |
| JP2002537258A5 (https=) | ||
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| WO2024059664A3 (en) | Salts and esters of apx3330 and therapeutic uses thereof | |
| MX2024002146A (es) | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. | |
| US3922340A (en) | Pharmaceutical compositions for treating lung diseases | |
| CN1466465A (zh) | 肥胖或脂肪肝的预防或治疗药物 | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| JP5765738B2 (ja) | ロスバスタチンおよびアトルバスタチン誘導体 | |
| MX2025001887A (es) | Formas cristalinas de un inhibidor de pcsk9, composiciones y usos | |
| JP2003055217A (ja) | 医薬組成物 | |
| JP5738205B2 (ja) | アトルバスタチンラクトールの薬物としての使用 | |
| WO2023044315A3 (en) | Kca3.1 inhibitors for podocyte protection | |
| US20080132561A1 (en) | Materials and Methods for Treating Hypercholesterolemia | |
| BR0214293A (pt) | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo | |
| US8685374B2 (en) | EDTA containing compositions and uses thereof | |
| WO2024259310A3 (en) | Passive permeable pcsk9 antagonist compounds | |
| NZ797598A (en) | Tetrazole derivatives as trpa1 inhibitors |